Shares of Cancer Genetics Inc (NASDAQ:CGIX) have earned an average rating of “Hold” from the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $6.00.
Several equities analysts recently commented on CGIX shares. Zacks Investment Research raised shares of Cancer Genetics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. HC Wainwright set a $6.00 price objective on shares of Cancer Genetics and gave the company a “buy” rating in a research note on Tuesday, February 6th. ValuEngine raised shares of Cancer Genetics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Finally, Maxim Group set a $6.00 price objective on shares of Cancer Genetics and gave the company a “buy” rating in a research note on Wednesday, December 13th.
A number of large investors have recently modified their holdings of the stock. Northern Trust Corp grew its stake in Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after acquiring an additional 12,168 shares in the last quarter. Granahan Investment Management Inc. MA grew its stake in Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after acquiring an additional 49,371 shares in the last quarter. Two Sigma Securities LLC grew its stake in Cancer Genetics by 363.0% during the fourth quarter. Two Sigma Securities LLC now owns 67,677 shares of the medical research company’s stock valued at $125,000 after acquiring an additional 53,061 shares in the last quarter. Perkins Capital Management Inc. grew its stake in Cancer Genetics by 22.7% in the 4th quarter. Perkins Capital Management Inc. now owns 989,700 shares of the medical research company’s stock worth $1,831,000 after buying an additional 183,000 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Cancer Genetics by 61.9% in the 2nd quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock worth $2,041,000 after buying an additional 197,619 shares in the last quarter. 17.96% of the stock is owned by institutional investors.
Cancer Genetics (NASDAQ:CGIX) traded up $0.08 on Friday, hitting $1.98. 36,792 shares of the stock traded hands, compared to its average volume of 132,124. The stock has a market capitalization of $48.48, a P/E ratio of -1.96 and a beta of 1.24. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.01 and a quick ratio of 2.01. Cancer Genetics has a 52-week low of $1.55 and a 52-week high of $5.30.
TRADEMARK VIOLATION WARNING: “Cancer Genetics Inc (CGIX) Receives $6.00 Consensus Price Target from Brokerages” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://ledgergazette.com/2018/03/20/cancer-genetics-inc-cgix-receives-6-00-consensus-price-target-from-brokerages.html.
About Cancer Genetics
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.